soul trial oral semaglutide cardiovascular outcomes results SELECT soul trial oral semaglutide cardiovascular

Clinical studies have shown that clients taking tirzepatide can achieve reductions in body weight of 15% or more, depending on the dose and duration of treatment

According to the International Diabetes Federation, 1 in 8 adults, about 783 million people, will live with diabetes by 2045, and more than 90% of them will have T2DM (The Idf Diabetes Atlas, 2021)

By signaling the hypothalamus, it reduces the drive to consume food

The cytokines TNF, IL-6, and chemokines activate cellular pathways such as the MAPK, and JAK/STAT pathways and activate TGF- receptors that promote inflammation and stimulate fibroblast/pericyte activation